Proteasomal insensitivity of apoptin in tumor cells
Henriëtte L Lanz1, Johnny Suijker, Mathieu H M Noteborn
1Department of Molecular Genetics, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands. h.lanz@chem.leidenuniv.nl
Abstract:
The small viral protein apoptin is capable of inducing apoptosis selectively in human tumor cells. In normal cells apoptin localizes in the cytoplasm where it forms aggregates, becomes epitope-shielded and eventually degraded. By inhibiting the proteasome activity with the chemical inhibitors bortezomib and Ada-Ahx(3)L(3)VS apoptin levels can be stabilized in normal cells similar to the tumor suppressor p53 protein. In contrast, proteasome inhibition in tumor cells did not affect the apoptin stability while it still stabilized p53 levels. Apparently, apoptin is degraded by proteasomal activity in normal human cells, a process that no longer takes place in tumor cells. This loss of proteasomal susceptibility appears to be specific for apoptin.
Insights
Viral protein apoptin induces apoptosis in tumor cells. Proteasome inhibitors stabilize apoptin in normal cells, but not tumor cells, indicating tumor cells evade apoptin degradation.
Area of Science:
- Molecular Biology
- Virology
- Cancer Research
Background:
- Apoptin, a viral protein, selectively induces apoptosis in human tumor cells.
- In normal cells, apoptin is degraded via proteasomal activity after cytoplasmic aggregation.
- Tumor cells exhibit resistance to apoptin-induced apoptosis.
Purpose of the Study:
- To investigate the role of proteasomal degradation in apoptin's selective tumor cell activity.
- To determine if inhibiting proteasome activity affects apoptin stability in normal versus tumor cells.
Main Methods:
- Utilizing proteasome inhibitors (bortezomib, Ada-Ahx(3)L(3)VS) to block proteasome activity.
- Comparing apoptin and p53 protein levels in normal and tumor cells under proteasome inhibition.
- Analyzing the degradation pathway of apoptin in different cell types.
Main Results:
- Proteasome inhibition stabilized apoptin levels in normal cells, similar to p53.
- In tumor cells, proteasome inhibition did not affect apoptin stability.
- p53 levels were stabilized in both normal and tumor cells upon proteasome inhibition.
- Apoptin degradation by proteasomes occurs in normal cells but is lost in tumor cells.
Conclusions:
- Apoptin is degraded by the proteasome in normal human cells.
- Tumor cells have lost susceptibility to apoptin proteasomal degradation.
- This selective loss of proteasomal degradation contributes to apoptin's tumor-specific activity.
More Related Videos
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Extrinsic Apoptotic Pathway
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Abnormal Proliferation


